The Effect of Atorvastatin on Endothelial Cell Dysfunction in Chronic Kidney Disease
试验速览
- 阶段
- 4 期
- 状态
- 终止
- 入组人数
- 1
- 主要终点
- Improved Counts of Endothelial Progenitor Cells
研究概览
简要总结
The purpose of this study is to see if patients with chronic kidney disease have endothelial cells that don't function properly, which is thought to be a marker for cardiovascular risk. Endothelial cells line the heart and blood vessels. The investigators will treat your high cholesterol with a cholesterol-lowering drug (atorvastatin, or Lipitor). They will determine if this cholesterol lowering drug improves subjects' cholesterol as well as the function of endothelial cells.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 80 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Stage 3, 4 and 5 chronic kidney disease (not on dialysis)
- •Hyperlipidemia requiring cholesterol lowering therapy
- •Aged 18 to 80 years old
- •Ability to provide informed consent
排除标准
- •Patients requiring multiple cholesterol reducing agents
- •Patients with neovascularization present, such as neoplasm, active wounds, or significant retinopathy
- •Patients with contraindications or allergy to statins
研究组 & 干预措施
Atorvastatin
Subjects will be treated with atorvastatin 10 mg/day for 30 days. The study team will obtain one blood and urine sample at baseline prior to starting atorvastatin therapy, and again after 30 days of drug therapy. The study team will do ultrasound imaging of the arm in which a probe will be placed over the blood vessels to measure the diameter of the artery and how this changes after a blood pressure cuff is inflated and then deflated. Subjects will take one nitroglycerine tablet during the ultrasound imaging.
干预措施: Atorvastatin (Drug)
结局指标
主要结局
Improved Counts of Endothelial Progenitor Cells
时间窗: baseline, 30 days
Improvement of endothelial cell (EC) dysfunction will be assessed by improved counts of endothelial progenitor cells.
次要结局
未报告次要终点